Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
Paul M. Ridker(Herlev Hospital), Patrick Commerford, S.D. Anker, Tamás Forster(Brigham and Women's Hospital), Hiroaki Shimokawa(Tohoku University), Jan H. Cornel(Brigham and Women's Hospital), Hisao Ogawa(Kumamoto University Hospital), Petar Otašević, Alessandro Fucili, Jacques Genest(McGill University Health Centre), Ki‐Bae Seung, Wolfgang Köenig(German Centre for Cardiovascular Research), Francisco Antônio Helfenstein Fonseca(Universidade Federal de São Paulo), George Varigos, Robert J. Glynn(Brigham and Women's Hospital), Peter Sinnaeve(Brigham and Women's Hospital), Jean MacFadyen(Brigham and Women's Hospital), Peter Siostrzonek(Unknown), Irina Veze, Mitja Lainščak, Félix Medina, Renata Cífková(Brigham and Women's Hospital), Alberto Lorenzatti(Brigham and Women's Hospital), Nina Gotcheva, L Vida-Simiti(Brigham and Women's Hospital), Birutė Petrauskienė, John J.P. Kastelein(QRx Pharma (United States)), Tor Ole Klemsdal, Zhanna Kobalava(Peoples' Friendship University of Russia), Yong Huo(Sun Yat-sen University), Davor Miličić, Leon Salvador, Miguel Urina‐Triana, Axel F. Sigurðsson, Tom Thurén(Novartis (Switzerland)), Daniel Pella(Brigham and Women's Hospital), Athanasios Manolis, Fernando Wyss, Prem Pais(Brigham and Women's Hospital), Peter Libby(Brigham and Women's Hospital), José Carlos Nicolau(Hospital São Paulo), Riina Vettus, Andrzej Budaj
Cited by 881
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
A Short Physical Performance Battery Assessing Lower Extremity Function: Association With Self-Reported Disability and Prediction of Mortality and Nursing Home Admission
|Journal of Gerontology|1994|9.7k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k